甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎的疗效与安全性探讨  

Efficacy and safety of methylprednisolone combined with azithromycin in the treatment of refractory Mycoplasma pneumonia in children

作　　者：贾斐 JIA Fei(Jining first people's Hospital,Shandong Jining 272000,China)

机构地区：[1]济宁市第一人民医院,山东济宁272000

出　　处：《中西医结合心血管病电子杂志》2020年第5期3-3,共1页Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的本文是为了探讨在医治小儿难治性支原体肺炎过程中,阿奇霉素联合甲泼尼龙发挥的效用。方法选取2017年4月21~2019年4月20日收入医治的78位患难治性支原体肺炎儿童,随机分成实验组(甲泼尼龙联合阿奇霉素)和参考组(阿奇霉素),各39人。详细记录医治效果。结果参考组的总体医治有效率很明显比实验组小,差异有统计学意义(P<0.05);两组在不良副作用方面不存在差别。结论阿奇霉素药品与甲泼尼龙药品一起使用,明显增强了难治性支原体肺炎的医治成效。Objective The aim of this article is to find the effect of Azithromycin combined with methylprednisolone in the treatment of refractory Mycoplasma pneumonia in children.Methods 78 children with refractory Mycoplasma pneumonia were randomly divided into experimental group(methylprednisolone combined with azithromycin)and reference group(azithromycin),39 in each group.Results The total effective rate of the reference group was significantly lower than that of the experimental group,P value was less than 0.05;there was no difference in adverse side effects between the two groups.CONCLUSION Azithromycin combined with methylprednisolone can significantly enhance the therapeutic effect of refractory Mycoplasma pneumonia.

关 键 词：甲泼尼龙联合阿奇霉素 医治效用 不良副作用 难治性支原体肺炎 

分 类 号：R969.3[医药卫生—药理学]